AGMB News

Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook

Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook

Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease

Agomab Announces Results of Annual General Meeting

Agomab to Participate in Upcoming Conferences

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

Agomab Announces Closing of Initial Public Offering

Agomab Announces Pricing of Initial Public Offering